Skip to content

Alexander de Foe

5 papers in the library · 42 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience.

Brain and Behavior July 1, 2025 Hugh McGovern, L Bajo, G Hassed et al. 1 citation

The phenomenology of psychedelic experiences has been a long-standing point of interest to researchers. However, internal experience has been relatively relegated, with much work done on the clinical outcomes of psychedelic therapies. Our reflexive thematic analysis revealed that structurally, people on fora write about their experiences sequentially, considering factors prior to (preparatory),...

Predictors of Psychedelic Experience: A Thematic Analysis

Journal of Psychoactive Drugs October 5, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 33 citations

Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of factors predicting psychedelic experience is essential to clinical progress and wider harm reduction frameworks. Ketamine, MDMA, LSD and psilocybin were selected for comparison due to their promising...

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions

Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 8 citations

Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...

Psychedelic Assisted Therapy for Major Depressive Disorder: A Review

June 27, 2021 Annie M. Mccartney, Hugh McGovern, Alexander de Foe preprint

Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this...